| Address |
200 Bay Street South Tower, Suite 2800 Toronto, M5J 2J3 Canada |
|
| Address type | Registered Office Address | |
| Address province | Ontario |
| Corporation ID | 7872372 | |
| Business number | 816561112 | |
| Status | Active | |
| ACT | Canada Business Corporations Act | |
| Anniversary date | 05/25/2011 | |
| Last annual filing | 2026 | |
| Data verified | 10/31/2026 |
Approximate location (postal code area): GeoNames (CC BY 4.0).
| Name | Effective date | Type | Current |
|---|---|---|---|
| Entos Pharmaceuticals Inc. | 05/25/2011 | Corporate Name | true |
last updated: 2026-10-30
10 federal grants and contributions between 2018 and 2025 with a total value of $88,648,300.
| Start date | Department and program | Value |
|---|---|---|
| 11/03/2025 |
National Research Council Canada Industrial Research Assistance Program – Contributions to Firms (contribution) Development of an Inhaled Genetic Medicine for Pre-Exposure Prophylaxis of H5N1 Influenza Seasonal and pandemic influenza continue to pose substantial threats to public health and highly pathogenic strains such as H5N1 carry the potential for devastating outbreaks. The Firm proposes to develop a novel long-acting pre-exposure prophylaxis platform to deliver DNA-encoded broadly... |
$764,000 |
| 08/01/2025 |
National Research Council Canada Industrial Research Assistance Program – Contributions to Firms (contribution) UK Biomanufacturing - 10143578 - NPmsDNA2024 - Development of in vivo targeted non-viral gene therapies As part of the international consortium project “NPmsDNA2024: Development of in vivo targeted non-viral gene therapies” this project will focus on leveraging Entos’ Fusogenix PLV formulations optimized for delivery of DNA-based genetic medicines to target cell types of the retina to address unmet... |
$130,700 |
| 04/01/2025 |
National Research Council Canada Industrial Research Assistance Program – Contributions to Firms (contribution) In Vivo Validation of Fusogenix Formulations Optimized for Delivery of Genetic Medicines to the Trabecular Meshwork of the Eye In partnership with a large Multinational Pharmaceutical Partner, the Firm will evaluate the safety and effectiveness of its Fusogenix formulations optimized for delivery of genetic medicines to the trabecular meshwork of the eye to treat ophthalmological diseases. The project will validate... |
$250,000 |
| 02/13/2025 |
Innovation, Science and Economic Development Canada SIF Stream2- Growth (other transfer payment) Innovation and Biomanufacturing Centre project This project will support the establishment of an innovation research and development (R&D) centre and a commercial scale, good manufacturing practices (GMP) manufacturing facility in Edmonton, Alberta for the production of novel genetic medicines. |
$62,000,000 |
| 11/01/2024 |
National Research Council Canada Industrial Research Assistance Program – Contributions to Firms (contribution) MNC Collab - FOCUS2024 - Fusogenix Formulation Development for Safe and Potent Delivery of Nucleic Acid Cargoes in the Eye As part of Multinational Corporate Collaboration Program, the project “Fusogenix Formulation Development for Safe and Potent Delivery of Nucleic Acid Cargoes in the Eye” will focus on the evaluation of the safety and effectiveness of a gene, encoded in partner mRNA, in correcting an... |
$75,000 |
| 09/01/2022 |
National Research Council Canada Industrial Research Assistance Program – Contributions to Firms (contribution) COVID-19 Vaccine: Phase 3 Clinical Trial of DNA-Based Vaccine Booster Covigenix VAX-001-1c Entos has developed Covigenix VAX-001, a DNA Proteo-Lipid Vehicle (PLV) vaccine intended for the prevention of COVID-19 infection by SARS-CoV-2. In this project, Entos will advance the VAX-001-1c bivalent vaccine candidate through Phase 3 clinical trials to establish its safety and immunogenicity... |
$10,000,000 |
| 11/01/2021 |
National Research Council Canada Industrial Research Assistance Program – Contributions to Firms (contribution) COVID-19 Vaccine: Phase 2 clinical trial of DNA-based vaccine Covigenix VAX-001 Entos has developed Covigenix VAX-001, a DNA Proteo-Lipid Vehicle (PLV) vaccine intended for the prevention of COVID-19 infection by SARS-CoV-2. In this project, Entos will advance the VAX-001 vaccine candidate through Phase 2 clinical trials to establish its safety and immunogenicity in healthy... |
$5,200,000 |
| 09/01/2020 |
National Research Council Canada Industrial Research Assistance Program – Contributions to Firms (contribution) COVID-19 Vaccine: Phase 1 clinical trial of DNA-based vaccine Covigenix VAX-001 Entos has developed Covigenix VAX-001, a DNA Proteo-Lipid Vehicle (PLV) vaccine intended for the prevention of COVID-19 infection by SARS-CoV-2. In this project, Entos will advance the VAX-001 vaccine candidate through Phase 1 clinical trials to establish its safety and immunogenicity in healthy... |
$10,000,000 |
| 05/01/2020 |
National Research Council Canada Industrial Research Assistance Program – Contributions to Firms (contribution) COVID-19 Response: Rapid Prototyping and Deployment of a Fusogenix Vaccine and Immuno-therapeutic against COVID-19 This project utilizes the Entos Fusogenix DNA delivery platform to rapidly develop, validate, manufacture and deploy countermeasures to protect the majority of the Canadian population from SARS-CoV-2 infection and COVID-19 disease. |
$100,000 |
| 10/01/2018 |
National Research Council Canada Industrial Research Assistance Program – Contributions to Firms (contribution) Towards Single-Step manufacturing of LNP Gene Therapy The goal of this project is to establish a method to synthesize Fusogenix DNA lipid nanoparticles using a single step manufacturing process. To achieve this, we will evaluate a number of methods to incorporate our fusogenic proteins into lipid nanoparticles using the Precision Nanosystems... |
$128,600 |
Source: Government of Canada, proactive disclosure of grants and contributions. Contains information licensed under the Open Government Licence – Canada.
| Date | Type | Section |
|---|---|---|
| 09/03/2019 | Amendment | 6 |
| 01/24/2018 | Amendment | 6 |
| 05/13/2016 | Amendment | 6 |
| 05/11/2016 | Revival | |
| 06/29/2014 | Dissolution | 14 |
| 05/25/2011 | Incorporation |
| Meeting date | Type of corporation | Year of filing |
|---|---|---|
| 05/25/2016 | Non-distributing corporation with 50 or fewer shareholders | 2017 |
| 04/18/2016 | Non-distributing corporation with 50 or fewer shareholders | 2016 |
| 04/18/2016 | Non-distributing corporation with 50 or fewer shareholders | 2015 |